Idiopathic Pulmonary Fibrosis Cohort of TCM

NCT07162870 · tracked via the Priya Life Science China tracker

Sponsor

Henan University of Traditional Chinese Medicine

Phase

Observational

Started

2025-09-05

Last updated

2025-09-09

Condition(s) studied

Idiopathic Pulmonary Fibrosis (IPF)

Investigational drug(s) / intervention(s)

Traditional Chinese medicine (TCM)Non-traditional Chinese medicine (non-TCM)

Traditional Chinese medicine (TCM): Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure is defined as taking the medication continuously for more than 3 months per year, or intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group is divided into an exposed group (TCM cohort) and an unexposed group (non-TCM cohort).

Non-traditional Chinese medicine (non-TCM): All intervention measures that do not meet the criteria for TCM exposure are regarded as non-TCM exposure.

Study summary

This study, based on past registration records, evaluates the clinical efficacy of traditional Chinese medicine in treating IPF in the real world, identifies advantageous populations and clinical targets, and provides references for precision traditional Chinese medicine treatment.

Eligibility

Sex

ALL

Min age

40 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Patients diagnosed with IPF; 2. Age ≥ 40 years old; 3. Voluntary participation in this study,And sign the informed consent form. Exclusion Criteria: 1. Patients with confusion, dementia, consciousness disorders, and various mental illnesses; 2. Patients who are unable to take care of themselves and have been bedridden for a long time.

Primary outcome measure(s)

Annual acute exacerbation rate — Up to week 104
The annual acute exacerbation rate will be calculated in each group at the end of the trial.

Trial sites (1)

Facility	City	Region	Status
The First Affiliated Hospital of Henan University of Chinese Medicine	Zhengzhou	Henan

More Henan University of Traditional Chinese Medicine trials in China

A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacterial Infections Recruiting

Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF Starting soon

Clinical Study on the Treatment of Chronic Airway Diseases (Asthma, Chronic Obstructive Pulmonary Disease) with Shu Fei Tie Starting soon

REspiratory diSEAse cohoRt Studies of CHinese Medicine for Asthma (RESEARCH- Asthma) Starting soon

TCM Cohort for Elderly CAP Starting soon

Other trials for the same condition

A Phase I Study of HW241045 in Healthy Subjects Starting soon

Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy Starting soon

A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Recruiting

Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis Starting soon

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07162870 on ClinicalTrials.gov ↗ ← All trials in China